MahaH. A.HussainMDFACP, FASCO

Oncology • Chicago, IL

Genitourinary Oncology, Hematologic Oncology

Physician

Join to view full profile

Dr. Hussain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hussain's full profile

Already have an account?

Office
675 N Saint Clair St
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106
Is this information wrong?

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1986 - 1989
Wayne State University School of MedicineResidency, Internal Medicine, 1984 - 1986
University of Baghdad College of MedicineClass of 1980

Certifications & Licensure

IL State Medical License 2016 - 2026
MI State Medical License 1984 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Giant of Cancer Care in Genitourinary Onclive, 2015
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2010
Join now to see all

Clinical Trials

SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Start of enrollment: 1995 May 01
Completed
Phase 3
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Start of enrollment: 1997 Mar 01
Completed
Phase 3
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy Start of enrollment: 1998 Oct 01
Completed
Phase 2
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Start of enrollment: 2000 Mar 01
Completed
Phase 2
S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2001 Jun 01
Completed
Phase 2
Cilengitide in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 2
Cilengitide in Treating Patients With Prostate Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 2
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
Completed
Phase 3
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer Start of enrollment: 2000 Sep 01
Completed
Phase 2
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 2
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma Start of enrollment: 2006 May 01
Terminated
Phase 2
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 2
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer Start of enrollment: 2005 Feb 01
Terminated
Phase 2
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer Start of enrollment: 2009 Oct 01
Terminated
Phase 2
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer Start of enrollment: 2011 Feb 01
Unknown status
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 2
Early Assessment of Treatment Response Using Functional Diffusion Mapping Start of enrollment: 2007 May 01
Completed
Not Applicable
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Start of enrollment: 2017 Jan 12
Active, not recruiting
Phase 2
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Start of enrollment: 2019 Nov 18
Active, not recruiting
Phase 1, Phase 2
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2019 Sep 20
Active, not recruiting
Phase 2
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2016 May 03
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather ...> ;European Urology Oncology. 2024 Mar 23
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Pro...
Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A Carducci, Matthew R Smith,...> ;Journal of Clinical Oncology. 2024 Mar 20
Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small.
Anthony V Serritella, Himisha Beltran, Tamara L Lotan, David J VanderWeele, Fatima Karzai, Ravi A Madan, Maha Hussain> ;The Oncologist. 2024 Mar 4
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.
Serritella, A., Hussain, M.> ;Current Treatment Options in Oncology. 2024 Mar 1
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Channing J Paller, Pedro C Barata, Justin Lorentz, Leonard J Appleman, Andrew J Armstrong, Tiffani A DeMarco, Robert Dreicer, Jo Ann B Elrod, Mark Fleming, Christopher...> ;The Prostate. 2024 Feb 1
2 citations
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations inand/orin the PROfound Trial.
Joaquin Mateo, Johann S de Bono, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Mustafa Özgüro...> ;Journal of Clinical Oncology. 2024 Feb 10
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Neal D Shore, Maha Hussain, Fred Saad, Karim Fizazi, Cora N Sternberg, David Crawford, Bertrand Tombal, Michael Cookson, Frank Verholen, Jay Jhaveri, Shankar Srinivasa...> ;The Oncologist. 2024 Mar 4
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Ugo De Giorgi, Neal D Shore, Fred Saad> ;Future Oncology. 2023 Sep 1
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.
Galina Gritsina, Ka-Wing Fong, Xiaodong Lu, Zhuoyuan Lin, Wanqing Xie, Shivani Agarwal, Dong Lin, Gary E Schiltz, Himisha Beltran, Eva Corey, Colm Morrissey, Yuzhuo Wa...> ;The Journal of Clinical Investigation. 2023 Aug 1
1 citations
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carc...
Thomas Powles, Zoe June Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stephane Oudard, Jürgen E Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, S...> ;European Urology. 2024 Feb 1
24 citations
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conferenc...
Sharifi, N., Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christ...> ;European Journal of Cancer. 2023 May 1
1 citations
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.
Anis A Hamid, Nicolas Sayegh, Bertrand Tombal, Maha Hussain, Christopher J Sweeney, Julie N Graff, Neeraj Agarwal> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 May 1
8 citations
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, Elena Castro, Ronald de Wit, Karim Fizazi, Silke Gillessen, Maha Hussain, Joaquin Mateo, Michael J Morris, David Olmo...> ;European Urology. 2023 Sep 1
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Ugo De Giorgi, Neal D Shore, Fred Saad> ;The Journal of Urology. 2023 Mar 1
28 citations
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARAS...
Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N Sternberg, E David Crawford, Neal Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Bögemann, D...> ;Journal of Clinical Oncology. 2023 Jul 10
Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm.
Anthony V Serritella, Maha Hussain, Fenton, S.> ;European Urology Focus. 2023 May 1
11 citations
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Thomas J Herzog, Ignace Vergote, Leonard G Gomella, Tsveta Milenkova, Tim French, Raffi Tonikian, Christian Poehlein, Maha Hussain> ;European Journal of Cancer. 2023 Jan 1
33 citations
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal T...
Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney,...> ;European Urology. 2023 Mar 1
7 citations
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A Carducci, Young Deuk Choi,...> ;Clinical Cancer Research. 2023 Jan 4
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Ugo De Giorgi, Maha Hussain, Neal Shore, Karim Fizazi, Bertrand Tombal, David Penson, Fred Saad, Eleni Efstathiou, Katarzyna Madziarska, Joyce Steinberg, Jennifer Sugg...> ;Future Oncology. 2022 Nov 1
2 citations
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
David J VanderWeele, Masha Kocherginsky, Sabah Munir, Brenda Martone, Vinay Sagar, Alicia Morgans, Walter M Stadler, Sarki Abdulkadir, Maha Hussain> ;Clinical Genitourinary Cancer. 2022 Dec 1
4 citations
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Matthew R Smith, Maha Hussain, Fred Saad, Karim Fizazi, Cora N Sternberg, David Crawford, Jan Manarite, David Muslin, Thomas Farrington, Bertrand Tombal> ;Future Oncology. 2022 Jul 1
55 citations
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G Bristow, Muhammad Bulbul, Or...> ;European Urology. 2022 Jul 1
4 citations
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G Bristow, Muhammad Bulbul, Orazi...> ;European Urology. 2022 Jul 1
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [...
Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G Bristow, Muhammad Bulbul, Orazi...> ;European Urology. 2022 Jul 1
Join now to see all

Journal Articles

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, Neeraj Agarwal, Przemyslaw Twardowski, The New England Journal of Medicine
Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients with Prostate Cancer
Sean Sachdev, Gregory Auffenberg, Maha Hussain, JAMA Oncology
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, MD, The New England Journal of Medicine

Authored Content

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients with Prostate CancerAugust 2020

Press Mentions

Darolutamide-Containing Triplet Regimen Ups Survival in mHSPC Regardless of Disease Volume, RiskMarch 6th, 2023
Maha Hussain, MD, on PSMA-PET in Metastatic Hormone-Sensitive Prostate CancerSeptember 8th, 2022
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred SaadJune 8th, 2022
Join now to see all